Israel Englander Champions Oncology, Inc. Transaction History

Millennium Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.11 - $6.81 $63,388 - $105,030	-15,423 Reduced 25.6%	44,830 $286,000
Q1 2023 May 15, 2023	BUY	$4.0 - $4.67 $4,204 - $4,908	1,051 Added 1.78%	60,253 $242,000
Q4 2022 Feb 14, 2023	BUY	$3.75 - $7.69 $17,925 - $36,758	4,780 Added 8.78%	59,202 $267,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.47 $13,511 - $17,746	1,874 Added 3.57%	54,422 $408,000
Q2 2022 Aug 15, 2022	SELL	$6.81 - $8.31 $8,532 - $10,412	-1,253 Reduced 2.33%	52,548 $425,000
Q1 2022 May 16, 2022	SELL	$7.26 - $8.53 $2,795 - $3,284	-385 Reduced 0.71%	53,801 $437,000
Q4 2021 Feb 14, 2022	SELL	$7.76 - $10.23 $48,306 - $63,681	-6,225 Reduced 10.3%	54,186 $433,000
Q3 2021 Nov 15, 2021	SELL	$9.11 - $10.96 $254,159 - $305,773	-27,899 Reduced 31.59%	60,411 $617,000
Q2 2021 Aug 16, 2021	BUY	$8.45 - $11.72 $746,219 - $1.03 Million	88,310 New	88,310 $908,000
Q2 2019 Aug 14, 2019	SELL	$7.51 - $10.12 $111,666 - $150,474	-14,869 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$7.89 - $12.23 $2,580 - $3,999	-327 Reduced 2.15%	14,869 $146,000
Q4 2018 Feb 14, 2019	SELL	$7.29 - $15.27 $74,161 - $155,341	-10,173 Reduced 40.1%	15,196 $119,000
Q3 2018 Nov 14, 2018	BUY	$5.82 - $17.47 $147,647 - $443,196	25,369 New	25,369 $443,000
Q1 2018 May 15, 2018	SELL	$3.39 - $4.39 $48,015 - $62,179	-14,164 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$3.17 - $4.16 $24,894 - $32,668	-7,853 Reduced 35.67%	14,164 $55,000
Q3 2017 Nov 14, 2017	BUY	$3.03 - $3.97 $66,711 - $87,407	22,017	22,017 $81,000

5.81M

3.3K

6.1K

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $53.7M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.